Dergiler / Medicine Science / 2022 / Cilt: 11 - Sayı: 1

AVIPTADIL; Class effect of a Synthetic VIP as a treatment option in COVID 19 patients with severe respiratory failure

Sayfa
433–438
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Final results from recently completed as well as all currently ongoing trials will clarify the class effect of this drug in the treatment of COVID 19 in future days.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Despite dynamic drug and vaccine developmental processes to reduce the disease burden of COVID 19, still the options for treatment are very limited.
📊
Temel Bulgular & Veri:VIP inhibits SARS COV-2 gene replication in human monocytes and viral replication in Calu -3 cells thus further reducing the generation of proinflammatory mediators Aviptadil, a synthetic form of VIP, is the only pulmonary therapeutic agent to have been granted Fast Track status by the US FDA and to be allowed into both phase 2/3 clinical trials Initial binding of Aviptadil with nsp10 & nsp 16 which may inhibit the 2 -O-MTase activity of the SARS-CoV nsp10/16 complex Aviptadil as a synthetic VIP has already been proved to be an effective option in the treatment of severe respiratory failures due to sepsis and other related lung injuries.
💡
Sonuç & Katkı:Final results from recently completed as well as all currently ongoing trials will clarify the class effect of this drug in the treatment of COVID 19 in future days.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Despite dynamic drug and vaccine developmental processes to reduce the disease burden of COVID 19, still the options for treatment are very limited. Vasoactive peptide (VIP) has diversified physiological action with specific features of lung protection-related activities. VIP inhibits SARS COV-2 gene replication in human monocytes and viral replication in Calu -3 cells thus further reducing the generation of proinflammatory mediators Aviptadil, a synthetic form of VIP, is the only pulmonary therapeutic agent to have been granted Fast Track status by the US FDA and to be allowed into both phase 2/3 clinical trials Initial binding of Aviptadil with nsp10 & nsp 16 which may inhibit the 2 -O-MTase activity of the SARS-CoV nsp10/16 complex Aviptadil as a synthetic VIP has already been proved to be an effective option in the treatment of severe respiratory failures due to sepsis and other related lung injuries. Interim analysis results of this drug use in respiratory failures caused by SARS COV-2 has evolved a new hope in regards to safety and efficacy. Final results from recently completed as well as all currently ongoing trials will clarify the class effect of this drug in the treatment of COVID 19 in future days.

🔖

Bu Makaleye Atıf Yap

CHAKRABORTY, D. S., CHOUDHURY, S., LAHİRY, S. (2022). AVIPTADIL; Class effect of a Synthetic VIP as a treatment option in COVID 19 patients with severe respiratory failure. Medicine Science, Cilt: 11 - Sayı: 1, 433–438. https://ajindex.com/articles/579606

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Chacko J, Unais M. Pharmacologic treatment of COVID-19: Evidencebased update. Indian J Respir Care. 2021
  2. 10,Suppl S1:34-8 2. Heustess AM, Allard MA, Thompson DK, et al. Clinical management of COVID-19: A Review of pharmacological treatment options. Pharmaceuticals. 2021
  3. Said SI, Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature.1970
  4. Li L, Hua S, Yue S, et al. Vasoactive intestinal polypeptide induces surfactant protein A expression in ATII cells through activation of PKC/c- Fos pathway. Peptides. 2010
  5. Mossel EC, Wang J, Jeffers S, et al. SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. Virology. 2008
  6. Tang H, Welton A, Ganea D. Neuropeptide regulation of cytokine expression: Effects of VIP and RO 25-1553. J Interferon Cytokine Res. 1995
  7. Voice JK, Grinninger C, Kong Y, et al. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell targeted type II VIP receptor transgenic mice. J Immunol. 2003
  8. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med. 2007
  9. Delgado, Mario Martínez, Carmen Pozo, David et al. Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-Activation Polypeptide (PACAP) Protect Mice from Lethal Endotoxemia Through the Inhibition of TNF-α and IL-6. J Immunol. 1999
  10. Berisha HI, Bratut M, Bangale Y, et al. New evidence for transmitter role of VIP in the airways: Impaired relaxation by a catalytic antibody. PulmPharmacolTher. 2002
  11. Sharma V, Delgado M, Ganea D. Granzyme B, a new player in activationinduced cell death is downregulated by vasoactive intestinal peptide in Th2 but not Th1 effectors J Immunol. 2005
  12. 97–110. 12. Said SI. Vasoactive intestinal peptide in the lung. Ann N Y Acad Sci. 1988
  13. Hasaneen NA, Foda HD, Said SI. Nitric oxide and vasoactive intestinal peptide as co-transmitters of airway smooth-muscle relaxation: analysis in neuronal nitric oxide synthase knockout mice. Chest. 2003
  14. Saga T, Said SI. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians. 1984
  15. Nagahiro I, Yano M, Boasquevisque CH, e